

Ronald V. Maier, M.D.

- HARBORVIEW INJURY PREVENTION AND RESEARCH CENTER
- CLINICAL TRIALS IN THE SURGICAL INTENSIVE CARE UNIT AT HARBORVIEW MEDICAL CENTER
- MODULATION OF THE EXCESSIVE INFLAMMATORY RESPONSE TO BIOMATERIALS
- MODULATION OF THE TRAUMA-RELATED MACROPHAGE INFLAMMATORY RESPONSE TO PREVENT ARDS, MOFS, AND DEATH

AWARDS:

National Institutes of Health

- NIGMS Institutional NRSA

Shock Society

- Young Investigator of the Year

American Trauma Society

- William S. Stone Award

FUNDING:

Centers for Disease Control

- National Center for Injury Prevention and Control

National Institutes of Health

- National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences
- Institutional National Research Service Award

National Science Foundation

Trauma remains a major cause of death and morbidity in America. It is the number one cause of mortality among 1-45 year olds, and is the overall number one contributor to loss of productive years of life in America. Death due to injury occurs in three peaks: 1) at the scene; 2) during the acute resuscitation phase, and 3) late, after one to two weeks of ICU support, secondary to multiple organ failure and sepsis. My research focuses on each of these phases. Prevention provides the best means to minimize deaths at the scene. Trauma system development and improvements in acute care including resuscitation will reduce early deaths and minimize subsequent morbidity. Finally, elucidation of the basic pathophysiology of severe injury will identify treatment modalities to prevent the autodestructive inflammatory response causing organ dysfunction and death following trauma.

Harborview Injury Prevention and Research Center

Dr. Maier is Associate Director of the Harborview Injury Prevention and Research Center (HIPRC). HIPRC is linked closely with the Northwest Regional Trauma Center at Harborview Medical Center. The goal of HIPRC is to diminish the impact of trauma on people's lives and to draw on the effectiveness of the Northwest Regional Trauma Center's injury prevention and trauma treatment programs. Established at HMC in 1985, HIPRC is a component of the University of Washington and the Schools of Medicine and Public Health.

Current projects include identifying the risk factors for injury while developing new techniques for the application of epidemiology in the field of trauma research. Further goals are to develop and utilize systematic, high-quality data systems to document the types, causes, treatment and consequences of injuries in a wide variety of settings. A particular focus is on assessment of outcomes and the impact of trauma system development. In addition, development and assessment of new, more effective means to resuscitate and treat injured patients along the entire spectrum of care from pre-hospital to rehabilitation is ongoing. Following are examples of current investigations:

1. *Evaluation of the Washington Pre-hospital Trauma Triage Instrument in a Population-Based Study:* Triage decisions are made by emergency medical care providers to distinguish patients who require care at a fully equipped trauma center from those whose injuries are less extensive. Excessive triage assignment to a major trauma center overburdens such centers with victims who could be effectively treated at a facility closer to their home. On the other hand, triage which underutilizes the major trauma centers in favor of local hospitals may place patients in facilities with inadequate resources and increased risk of poorer outcomes. Using selected population-based trauma registry data consisting of pre-hospital and hospital records, we will determine the accuracy of the state trauma triage instrument for distinguishing major trauma patients for care in major trauma centers, and modify patient distribution as appropriate.

2. Relationship Between Trauma Center Volume and

Outcome: The premise underlying regionalization of trauma care is that optimal outcomes can be achieved at greatest efficiency if care is restricted to relatively few dedicated trauma centers. Implicit in this premise is that higher patient volumes will lead to greater experience, and this experience translates into better outcomes. This relationship appears to hold for other areas of surgical care involving complex procedures, but in contrast, there is no such relationship when less complex procedures are evaluated. Previous studies evaluating the relationship between institutional volume and outcomes in trauma patients are difficult to interpret because of multiple logistic issues. We are

currently investigating two distinct cohorts of trauma patients to evaluate whether there is an institutional volume threshold at which optimal outcomes can be achieved for critically injured patients.

tion use tidal volumes of 10–15 ml/kg of body weight. These volumes are much larger than those in normal subjects at rest, but are frequently necessary to achieve normal values for partial pressure of arterial carbon dioxide and pH. Since atelectasis and edema reduce aerated lung volumes, inspiratory airway pressures are often excessively high to achieve these parameters, suggesting the presence of excessive distension or “stretch” of the remaining aerated lung.

Thus, this traditional approach to mechanical ventilation may exacerbate or perpetuate lung injury, and in contrast, the use of lower tidal volumes during ventilation may reduce or prevent this deleterious process. Previous uncontrolled studies suggest that

Until now, therapeutic approaches have focused on control or inhibition of single components of the overall inflammatory response.

currently investigating two distinct cohorts of trauma patients to evaluate whether there is an institutional volume threshold at which optimal outcomes can be achieved for critically injured patients.

Clinical Trials in the Surgical Intensive Care Unit at Harborview Medical Center

We are performing multiple ongoing trials based on the pathophysiologic response of the severely injured patient, many in conjunction with the Division of Pulmonary and Critical Care in the Department of Medicine. In particular, clinical studies and associated basic investigations are focused on the acute respiratory distress syndrome (ARDS) which affects critically ill and injured patients.

ARDS is largely responsible for the prolonged intensive care unit and hospital stay, and contributes significantly to mortality in these patients. Management is primarily supportive while the underlying disease process stabilizes and resolves. Attempts to reduce the consequences of ARDS have focused upon 1) pharmacologic manipulation of the inflammatory response and 2) modifying positive pressure ventilation techniques to reduce the potential iatrogenic ventilator-associated lung injury. Examples of current studies are:

1. *Low Tidal Volume Ventilation in ARDS:* The mortality rate from acute lung injury and ARDS is approximately 40–50%. Traditional approaches to mechanical ventila-

tion use tidal volumes of 10–15 ml/kg of body weight. These volumes are much larger than those in normal subjects at rest, but are frequently necessary to achieve normal values for partial pressure of arterial carbon dioxide and pH. Since atelectasis and edema reduce aerated lung volumes, inspiratory airway pressures are often excessively high to achieve these parameters, suggesting the presence of excessive distension or “stretch” of the remaining aerated lung.

Thus, this traditional approach to mechanical ventilation may exacerbate or perpetuate lung injury, and in contrast, the use of lower tidal volumes during ventilation may reduce or prevent this deleterious process. Previous uncontrolled studies suggest that

2. *Modulation of the Inflammatory Response:* The potentially auto-destructive excessive immunoinflammatory response is thought to contribute to the initiation and progression of ARDS and to ultimately affect patient outcome. Preliminary work at Harborview Medical Center (HMC) has shown a high incidence of Vitamin C and potential Vitamin E deficiency in trauma patients admitted to the HMC intensive care unit. A one month study of new patient admissions to Harborview Medical Center found that 64% of patients had plasma Vitamin C levels below the reference range, and 23% of patients had plasma Vitamin C levels less than 0.20mg/dL, indicating Vitamin C deficiency as defined by the World Health Organization. Reports from other institutions document a low plasma Vitamin C concentration in 28%–83% of select hospitalized patient populations, and 12%–21% in a random sample of all new hospital admissions.

An HMC study demonstrated that supplementing 3 gram/day of Vitamin C and 3 gram/day of Vitamin E

in patients with initially low levels resulted in plasma levels within the normal reference range within seven days. Patients not receiving supplements remained in the low reference range. The significance of Vitamin C deficiency in these patients is illustrated by a study of 78 patients with 105 fractures of the mandible treated at HMC: those patients who had fracture complications (infection, malunion) had significantly lower serum Vitamin C concentration than those with a good fracture outcome. In addition, patients with ARDS have been shown to have high levels of oxidants and suppressed levels of antioxidants, such as Vitamin C and Vitamin E, in bronchoalveolar lavage (BAL) specimens.

We hypothesize that plasma and tissue Vitamin C and E concentrations are significantly low in patients admitted to the intensive care units at HMC, and that routine supplementation of Vitamin C and E will elevate levels. Elevated levels of these two potent antioxidants may well protect against oxidant-induced injury in these severely injured and stressed patients and avoid the diffuse insult predisposing to ARDS and other organ dysfunction, and also to secondary nosocomial infections such as ventilator associated pneumonia and wound infections.

The study design is a prospective, observational study in which all trauma admissions to HMC ICU will have plasma Vitamin C and E levels determined at time of admission. Patients are randomized to receive standard care or antioxidant supplemented care with 1 gm q 8h orally Vitamin E and 1 gm q 8h IV of Vitamin C. These populations will be followed to determine their incidence of ARDS, duration in the ICU, mortality and infectious complications. In addition, BAL samples will be obtained to determine the effect on oxidant levels, cytokine production and activation state of the alveolar macrophage regarding intracellular signal transduction pathways.

Modulation of the Excessive Inflammatory Response to Biomaterials

The production and release of potent inflammatory mediators by tissue-fixed macrophages coordinate and orchestrate a series of biologic events that lead to either normal wound healing or abnormal chronic granulation and typical "foreign body" reaction. The goal of the experiments performed in conjunction with the University of Washington Engineered Biomaterials (UWEB) program funded by the NSF is to define the cell signaling processes that control the pro-inflammatory phenotype of the macrophage in response to various

biomaterials and that cause the subsequent chronic inflammatory response that leads to non-healing and extrusion of biomaterials.

Preliminary experiments have demonstrated that adherence by the macrophage to various surfaces primes the macrophage for activation. Subsequent steps in the inflammatory response lead to multi-nucleated giant cell formation and subsequent capsule formation, secretion of extracellular matrix, vascular budding, and fibroblast proliferation with thick collagen deposition. Prevention of the proinflammatory phenotype may well equate with prevention of foreign body reaction. In current studies we are investigating coating biomaterials with various molecules. These include osteopontin and various anti-inflammatory agents such as antioxidants including Vitamin E, and components of the extracellular matrix, such as hyaluronic acid derivatives, to test the subsequent response of adherent macrophages to inflammatory stimuli such as endotoxin.

In addition, we are studying materials of various selected pore sizes, to minimize cell spreading and to test environmental structural impact on macrophage response to inflammatory stimuli. End product analysis of inflammatory mediators such as TNF, procoagulant activity, and IL-8 along with the normally produced anti-inflammatory mediators IL-10 and PGE2 are monitored. These mediators exist in a delicate balance and time sequence to produce normal, as opposed to abnormal, wound healing and chronic inflammation.

In additional experiments, we will test the effect of end products of macrophage activation and modulation of macrophage activation. Using a chorioallantoic membrane fractal dimension and grid intersection assay we will monitor angiogenesis as a crucial component of both normal and abnormal wound healing and incorporation, or "healing," of biomaterials. The ultimate goal is to modulate the surface characteristics of biomaterials so that they may be adapted as "compatible" and elicit a normal host response and normal wound healing with incorporation of the biomaterial — "true healing."

Modulation of the Trauma-Related Macrophage Inflammatory Response to Prevent ARDS, MOFS, and Death

The last major area of investigation is based on the aberrant host immunoinflammatory response to trauma and sepsis. This auto-destructive response is thought to be responsible for the induction and persistence of the "malignant systemic inflammatory response" underlying ARDS and multiple organ failure syndrome (MOFS).

ARDS and MOFS are the major determinants of late death following trauma.

The primary etiology of ARDS and MOFS leading to late mortality following trauma is the clinical "sepsis syndrome" or systemic inflammatory response syndrome (SIRS). This diffuse inflammatory response causes disseminated tissue injury and subsequent organ dysfunction. The long-lived, highly diverse tissue fixed macrophage is a crucial central coordinator of both the normal and the aberrant host immunoinflammatory response. The macrophage is both primed and activated by a multitude of stimuli during the inflammatory response.

Until now, therapeutic approaches have focused on control or inhibition of single components of the overall inflammatory response. However, since the inflammatory response is replete with redundancy and feedback amplification mechanisms, it is appealing to take a broader approach to control the inflammatory response and subsequent injury to multiple diffuse organ beds. To achieve this goal in these basic laboratory investigations, we are focusing on the cellular and molecular mechanisms involved in macrophage signaling and activation by inflammatory stimuli and the subsequent

production of multiple inflammatory cytokines.

The goal is to develop therapeutic interventions based on controlling these intracellular transduction pathways and to modulate the over-aggressive macrophage response and the subsequent auto-destructive immunoinflammatory response. Currently we are studying the manipulation of cellular signal transduction mechanisms that control inflammatory mediator genes by altering the intracellular levels and release of calcium, the regulation of levels of cyclic AMP, and the delineation of regulatory protein kinase signal transduction pathways, particularly the MAP kinase family, including ERK1/2, SAPK, and r38. In addition, we are investigating signaling processes activated through formation of focal adhesion complexes induced by adherence of the monocyte/macrophage as critical to the host inflammatory cell response. A major focus is on the ability of antioxidants, such as vitamin E, or cytoskeletal inhibitors, such as cytochalasin D, to modify the cellular response to inflammatory stimuli. Elucidation and control of these macrophage cellular mechanisms will permit development of future safe therapies to prevent ARDS, MOFS, and death in the critically ill surgical patient.

RELATED PUBLICATIONS:

1. Arbabi S, Rosengart M, Garcia I, Jelacic S, Maier R: Priming Interleukin-8 production The role of platelet-activating factor and p38. *Arch Surg*, Dec 1999; 134(12):1348-53.
 2. Nathens A, Jurkovicj J, Rivara F, Maier R: Effectiveness of state trauma systems in reducing injury-related mortality: A national evaluation. *J Trauma*, 2000; 48(1):25-31.
 3. Rosengart MR, Arbabi S, Garcia I, Maier RV: Interactions of calcium/calmodulin-dependent protein kinases (CaMK) and extracellular-regulated kinase (ERK) in monocyte adherence and TNF α production. *Shock*, 2000; 13(3):183-189.
 4. Bulger EM, Jurkovich GJ, Gentilello LM, Maier RV: Current clinical options for the treatment and management of ARDS. *J Trauma*, 2000; 48(3):562-572.
 5. Nathens A, Jurkovich G, Cummings P, Rivara F, Maier R: The effect of organized systems of trauma care on motor-vehicle crash mortality. *JAMA*, 2000; 283(15):1990-1994.
 6. Steinberg KP, Maier RV, Schoenfeld D, Thompson BT: Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: The ARDS Clinical Trials Network. *JAMA*, 2000; 283(15):1995-2002.
 7. Bulger EM, Maier RV: Lipid Mediators in the pathophysiology of critical illness. *Critical Care Medicine*, 2000; 28(4) (Suppl.) N27-N36.
 8. Brundage SI, McGahn R, Jurkovich J, Mack C, Maier RV: Incidence of adult respiratory distress syndrome as a function of the timing of femur fixation. *Proceedings: 5th International World Congress on the Pathophysiology, Immune Consequences and Therapy of Trauma, Shock and Sepsis*, Munich, Germany March 2000. Monduzzi Editore S.p.A, Bologna, Italy, pp. 113-118, 2000.
 9. The ARDS Network: A trial of traditional tidal volume versus lower tidal volume ventilation in acute lung injury and acute respiratory distress syndrome. *NEJM*, 2000; 342(18):1301-1308.
 10. Arbabi S, Rosengart R, Garcia, I, Maier R: Hypertonic saline induces prostacyclin production by increasing cyclooxygenase-2 expression. *Surg*, 2000; 128(2) 198-205.
-

DEPARTMENT CO-INVESTIGATORS:

Sam Arbabi, M.D. / Michael K. Copass, M.D. / Joe Cushieri, M.D. / Iris Garcia / Lawrence Gentilello, M.D. / David Gourlay, M.D. / Gregory Jurkovich, M.D. / Timothy Pohlman, M.D. / Nicholas Vedder, M.D. / Robert Winn, Ph.D.

OTHER CO-INVESTIGATORS:

Cecelia M. Giacelli, Ph.D.; UW Department of Bioengineering / **David P. Grossman, M.D.;** UW Department of Pediatrics and HIPRC Co-Director / **Tom Horbett, Ph.D.;** UW Department of Bioengineering / **Leonard Hudson, M.D.;** UW Department of Pulmonary Critical Care Medicine / **Terrance Kavanagh, Ph.D.;** UW Department of Pulmonary and Critical Care Medicine / **Tom Koepsell, Ph.D.;** Chair, UW Department of Epidemiology / **Frederick T. Rivara, M.D., M.P.H.;** UW Department of Pediatrics and HIPRC Director / **Patrick S. Stayton, Ph.D.;** UW Department of Bioengineering / **Kenneth Steinberg, M.D.;** UW Department of Pulmonary and Critical Care Medicine
